Follow us on:

Linkedin Facebook

N4 Pharma to host webinar on collaboration agreement with SRI International

N4 Pharma

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, will provide a pre-recorded webinar relating to the Company’s recent Collaboration Agreement with SRI International Inc. which was announced on 25 April 2024.

The webinar will be available for viewing on 7 May 2024 at 10:00 BST, via the Company’s Investor Hub.

Investors will be notified via email of the presentation if they have signed up to the Investor Hub in advance, which can be done here: investors.n4pharma.com/auth/signup.

Investors are invited to submit questions in advance via N4 Pharma’s Investor Hub, and CEO Nigel Theobald will address as many as possible. Register and submit questions at: investors.n4pharma.com

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    Latest Company News

    N4 Pharma plc

    N4 Pharma collaborates with SRI International to combine Nuvec and FOX Three MGS technology

    N4 Pharma Plc partners with SRI International to combine Nuvec® with FOX Three MGS, aiming to enhance nucleotide therapies for cancer and vaccines.
    N4 Pharma

    N4 Pharma achieves material advancements in the capabilities of Nuvec®

    N4 Pharma Plc (LON:N4P) unveils its audited results for 2023, showcasing advancements in its innovative Nuvec® delivery system for cancer treatments and vaccines.
    N4 Pharma plc

    N4 Pharma provides Positive Update on Nuvec® oral delivery research

    N4 Pharma Plc (LON:N4P) updates on successful oral delivery research for Nuvec® system, showing potential for cancer treatment and vaccines. CEO Nigel Theobald shares insights.
    N4 Pharma plc

    N4 Pharma provides encouraging update on its ongoing in vitro siRNA research work

    N4 Pharma Plc provides an update on its in vitro siRNA research work, showcasing the versatility of their Nuvec® delivery system for cancer treatments.
    N4 Pharma

    N4 Pharma’s Nuvec® granted patent in India

    N4 Pharma Plc announces the granting of a patent for its Nuvec® delivery system in India, adding to its global portfolio of granted patents.
    N4 Pharma plc

    N4 Pharma’s Nanogenics signs contract for pre-clinical study of ECP105 for Glaucoma treatment

    N4 Pharma's subsidiary, Nanogenics, has signed a contract to prepare its ECP105 product for pre-clinical studies in Glaucoma treatment.

      Latest interviews

      View all interviews 

      Company Presentations

      View all Company Presentations

      Brokers Talk

      View all Broker Talk

      FTSE 100 News

      Search

      Search

      Green News

      View all Sustainable sectors, Plcs and news  

      Q&A's

      View all Question and Answers

      Funds

      View all Funds, Market Insights and news

      UK Broker Ratings

      Hardman & Co

      Don't Miss Our News Alerts

      Subscribe Free

      Find us on:

      Linkedin Facebook

      Useful links

      Disclaimer

      You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

      © 2025 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.